Cross-Platform Identification and Validation of Uveal Melanoma Vitreous Protein Biomarkers
Investigative Opthalmology & Visual Science · 2023
DOI: 10.1167/iovs.64.14.14 ↗At a glance
Journal article in Investigative Opthalmology & Visual Science, 2023. Written by Gabriel Velez and 4 co-authors. Institution: Molecular Surgery Laboratory, Stanford University, Palo Alto, California, United States. Major MEDLINE topics: Uveal Neoplasms, Melanoma. Cited 10 times so far (Crossref); 51 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NEI NIH HHS.
Abstract (original language)
Purpose
The purpose of this study was to profile protein expression liquid vitreous biopsies from patients with uveal melanoma (UM) using mass spectrometry to identify prognostic biomarkers, signaling pathways, and therapeutic targets.
Methods
Vitreous biopsies were collected from two cohorts in a pilot study: comparative control eyes with epiretinal membranes (ERM; n = 3) and test eyes with UM (n = 8). Samples were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Identified proteins were compared to data from a targeted multiplex ELISA proteomics platform.
Results
A total of 69 significantly elevated proteins were detected in the UM vitreous, including LYVE-1. LC-MS/MS identified 62 significantly upregulated proteins in UM vitreous that were not previously identified by ELISA. Analysis of differential protein expression by tumor molecular classification (gene expression profiling [GEP] and preferentially expressed antigen in melanoma [PRAME]) further identified proteins that correlated with these classifications. Patients with high-risk GEP tumors displayed elevated vitreous expression of HGFR (fold-change [FC] = 2.66E + 03, P value = 0.003) and PYGL (FC = 1.02E + 04, P = 1.72E-08). Patients with PRAME positive tumors displayed elevated vitreous expression of ENPP-2 (FC = 3.21, P = 0.04), NEO1 (FC = 2.65E + 03, P = 0.002), and LRP1 (FC = 5.59E + 02, P value = 0.01). IGF regulatory effectors were highly represented (P value = 1.74E-16). Cross-platform analysis validated seven proteins identified by ELISA and LC-MS/MS.
Conclusions
Proteomic analysis of liquid biopsies may provide prognostic information supporting gene expression of tumor biopsies. The use of multiple protein detection platforms in the same patient samples increases the sensitivity of candidate biomarker detection and allows for precise characterization of the vitreous proteome.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Molecular Surgery Laboratory, Stanford University, Palo Alto, California, United States.
- Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, United States.
- Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
- Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States.
Funding
- NEI NIH HHS
Cite
APA
Velez, G., Wolf, J., Dufour, A., Mruthyunjaya, P., & Mahajan, V. B. (2023). Cross-Platform Identification and Validation of Uveal Melanoma Vitreous Protein Biomarkers. Investigative Opthalmology & Visual Science. https://doi.org/10.1167/iovs.64.14.14
Vancouver
Velez G, Wolf J, Dufour A, Mruthyunjaya P, Mahajan VB. Cross-Platform Identification and Validation of Uveal Melanoma Vitreous Protein Biomarkers. Investigative Opthalmology & Visual Science. 2023. doi:10.1167/iovs.64.14.14
BibTeX
@article{Velez2023,
author = {Velez, Gabriel and Wolf, Julian and Dufour, Antoine and Mruthyunjaya, Prithvi and Mahajan, Vinit B},
title = {Cross-Platform Identification and Validation of Uveal Melanoma Vitreous Protein Biomarkers},
journal = {Investigative Opthalmology & Visual Science},
year = {2023},
doi = {10.1167/iovs.64.14.14}
}
EUVIMED